METHOD OF SELECTING TREATMENT TACTICS FOR PATIENTS WITH ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL DISORDERS Russian patent published in 2023 - IPC A61K31/553 A61K31/5377 A61K31/5415 A61K31/407 A61K31/496 A61K31/495 A61K31/4985 A61K31/4468 A61P25/18 G01N33/53 C12Q1/6827 C12Q1/6837 C12Q1/6858 C12Q1/6874 G16B20/20 

FIELD: medicine; psychiatry; neurology; clinical pharmacology.

SUBSTANCE: invention can be used to select treatment tactics for the patients with antipsychotic-induced extrapyramidal disorders. The genotype characteristics of the patients are determined using microchips. When identifying homozygotes GG variant rs1799732 (4750dup) of the DRD2 gene, homozygotes TT variant rs1045642 of the ABCB1 gene and homozygotes AA variant CYP2D6*4 (rs3892097) of the CYP2D6 gene, the phenotype of antipsychotic-induced parkinsonism is determined. When identifying homozygotes of the TT variant rs6275 (67525 T>C) of the DRD2 gene and homozygotes of the TT variant CYP3A5*6 (rs10264272 C>T) of the CYP3A5 gene, the phenotype of antipsychotic-induced tardive dyskinesia is determined. When identifying homozygotes of the CC variant rs1800498 (59414 T>C) of the DRD2 gene, homozygotes of the TT variant rs1128503 of the ABCB1 gene and homozygotes of the TT variant CYP3A5*6 (rs10264272 C>T) of the CYP3A5 gene, the phenotype of antipsychotic-induced akathisia is determined. In accordance with the patient's phenotype, a choice of treatment tactics is made based on replacing the used antipsychotic with a typical antipsychotic selected from the group consisting of loxapine, molindone, perphenazine, trifluoperazine, thioridazine, asenapine, lurasidone, brexpiprazole, ziprasidone, cariprazine, lumateperone and pimavanserin.

EFFECT: method provides increased efficiency in choosing treatment tactics for patients with antipsychotic-induced extrapyramidal disorders due to a personalized approach based on determining the patient's genotype.

2 cl, 13 tbl, 3 ex